2003

Lancaster JM, Sayer R, Blanchette C, Calingaert B, Schildkraut J, Marks J, Berchuck A: High expression of TRAIL is associated with favorable ovarian cancer survival. Clin Cancer Res 9:762-6, 2003.

2004

Berchuck A, Iversen ES, Lancaster JM, Dressman HK, West M, Nevins JR, Marks JR: Prediction of optimal versus suboptimal cytoreduction of advanced stage serous ovarian cancer using microarrays.  Am J Obstet Gynecol 190:910-25, 2004.

Lancaster JM, Dressman H, Whitaker RS, Gray J, Marks JR, Nevins J, Berchuck A: Gene expression patterns that characterize advanced serous ovarian cancers. J Soc Gynecol Invest 11:51-9, 2004.

Berchuck A, Iversen ES, Lancaster JM, Dressman HK, West M, Nevins JR, Marks JR: Prediction of optimal versus suboptimal cytoreduction of advanced stage serous ovarian cancer using microarrays.  Oral Presentation, Am Gynecol Obstet Soc 2004.

Lancaster JM, Iversen ES, Dressman HK, West M, Nevins JR, Marks JR, Berchuck A: Identification of genes associated with ovarian cancer metastasis using microarrays. Oral Presentation, Soc Gynecol Oncol 2004.

Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, West M, Nevins JR, Marks JR: Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.  Int Gynecol Cancer Society Meeting 2004, First Prize plenary presentation.

2005

Sayer RA, Lancaster JM, Pittman J, Gray J, Whitaker RS, Marks JR, Berchuck A: High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol Oncol (in press).

Lancaster JM, Iversen ES, Dressman HK, West M, Nevins JR, Marks JR, Berchuck A: Prediction of complete response to primary chemotherapy in advanced stage serous ovarian cancer using microarrays.  Oral presentation, Soc Gynecol Oncol 2005.

Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, West M, Nevins JR, Marks JR: Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.  Clin Cancer Res (in press).